354 related articles for article (PubMed ID: 17406754)
21. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
22. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Berg T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
[TBL] [Abstract][Full Text] [Related]
24. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Buti M; Olive G; Stalgis C; Esteban R; Guardi J
Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
[TBL] [Abstract][Full Text] [Related]
25. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
Hass HG; Kreysel C; Fischinger J; Menzel J; Kaiser S
World J Gastroenterol; 2005 Sep; 11(34):5342-6. PubMed ID: 16149143
[TBL] [Abstract][Full Text] [Related]
26. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
[TBL] [Abstract][Full Text] [Related]
27. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
29. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V; Trimoulet P; Winnock M; Bernard PH; Bourlière M; Portal I; Rémy AJ; Szostak N; Lévy S; Tran A; Abergel A; Chêne G; Fleury H; Couzigou P;
J Hepatol; 2002 Jun; 36(6):819-26. PubMed ID: 12044534
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
31. Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients.
Wietzke-Braun P; Meier V; Neubauer-Saile K; Mihm S; Ramadori G
World J Gastroenterol; 2005 Oct; 11(39):6188-92. PubMed ID: 16273648
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hepatitis C virus infection in patients of northern India.
Hazari S; Panda SK; Gupta SD; Batra Y; Singh R; Acharya SK
J Gastroenterol Hepatol; 2004 Sep; 19(9):1058-65. PubMed ID: 15304125
[TBL] [Abstract][Full Text] [Related]
34. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
35. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
Bjøro K; Bell H; Hellum KB; Skaug K; Raknerud N; Sandvei P; Døskeland B; Maeland A; Lund-Tønnesen S; Myrvang B
Scand J Gastroenterol; 2002 Feb; 37(2):226-32. PubMed ID: 11843062
[TBL] [Abstract][Full Text] [Related]
36. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
37. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
39. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
40. Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y; Colle I; Van Vlierberghe H; Langlet P; Adler M; Bourgeois N; Brenard R; Michielsen P; Goossens A; Bruckers L;
Acta Gastroenterol Belg; 2008; 71(3):293-7. PubMed ID: 19198574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
